CSF3 and hematologic disorder: The present study was designed and conducted to investigate whether and to what extent the administration of MZ, an ‘immediate salvage’ strategy in donors with suboptimal CD34-cell counts after standard-dose G-CSF, affects the cellular composition of the graft in the setting of TCR-αβ/CD19-depleted haploidentical HSCT for children with hematological disorders.